Literature DB >> 15386802

Regulatory T-cells in type 1 diabetes.

Amy E Juedes1, Matthias G von Herrath.   

Abstract

Type 1 diabetes is a T-cell-mediated autoimmune disease, resulting in destruction of the insulin-producing beta cells in the pancreas. Disease progression is thought to involve the action of T-cells, particularly those producing Th1-type cytokines. Given the complexity in understanding the precise etiology of autoimmune diseases, the diversity of autoantigens, and the variability that exists between individual patients, it might be very difficult to eliminate autoaggressive T-cell responses without resorting to generalized means of immunosuppression. However, recent evidence shows that autoimmune processes are composed not only of autoaggressive T-cell responses but also of autoreactive regulatory components. Enhancing regulatory T-cell responses, therefore, has become an area of intense focus as a means of treating autoimmune diseases like type 1 diabetes. This review will concentrate on two different types of regulatory T-cells, the naturally occurring ('professional') CD4+CD25+ T-cells and antigen-induced ('adaptive') CD4+ Th2-like regulatory T-cells. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15386802     DOI: 10.1002/dmrr.508

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  2 in total

1.  Pre-incubation with interleukin-4 mediates a direct protective effect against the loss of pancreatic beta-cell viability induced by proinflammatory cytokines.

Authors:  A Kaminski; E R Kaminski; N G Morgan
Journal:  Clin Exp Immunol       Date:  2007-04-02       Impact factor: 4.330

2.  Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes.

Authors:  Ênio J Bassi; Pedro M M Moraes-Vieira; Carla S R Moreira-Sá; Danilo C Almeida; Leonardo M Vieira; Cláudia S Cunha; Meire I Hiyane; Alexandre S Basso; Alvaro Pacheco-Silva; Niels O S Câmara
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.